Understand supplement-label and claims concerns, then get product-specific help assessing your artwork and next steps.
A product that's already selling can be flagged overnight for a labeling violation — even when it's perfectly safe. Here's what actually triggers these letters, grounded in the rules, and how to stay clear.
Concerned about your supplement claims or an FDA notice? Use this guide to understand the issues. For help applying it to your label, claims, or correspondence, request a project assessment from our team.
Request Review Scope & PricingUnder DSHEA, a supplement may describe how an ingredient affects the normal structure or function of the body. It may not claim to diagnose, treat, cure, prevent, or mitigate a disease — that's a drug claim. The difference is entirely in the wording:
| Allowed — structure/function | Not allowed — disease claim |
|---|---|
| ✓ "Supports memory" | ✗ "Treats Alzheimer's" |
| ✓ "Helps maintain healthy cholesterol already in the normal range" | ✗ "Lowers high cholesterol" |
| ✓ "Supports joint comfort" | ✗ "Treats arthritis" |
| ✓ "Supports respiratory health" | ✗ "Cures colds and flu" |
| ✓ "Helps maintain healthy blood sugar already in the normal range" | ✗ "Treats diabetes" |
Any label carrying a structure/function claim must display the DSHEA disclaimer, in boldface, linked to the claim (typically with an asterisk):
You must also notify FDA within 30 days of first marketing the supplement with that claim (via FDA's electronic portal). The notification is not approval — substantiation stays your responsibility.
| Violation | Why it's a problem | Reg |
|---|---|---|
| 1. Disease claims (highest risk) | Makes the product an unapproved new drug and misbranded | 101.93 |
| 2. Incorrect Supplement Facts | Wrong format or inaccurate amounts | 101.36 |
| 3. Missing "dietary supplement" identity | Product not clearly identified | 101.3 |
| 4. Incomplete ingredient disclosure | Missing "other ingredients" or mislisting | 101.4 |
| 5. Missing U.S. responsible firm | Required name and address absent | 101.5 |
| 6. Allergen labeling errors | Undeclared major allergen (FALCPA applies) | FALCPA |
| 7. Misleading / unsubstantiated claims | Exaggerated or unsupported statements | FD&C Act |
FDA typically wants a written response within ~15 working days, with corrective actions and timelines.
You'll usually need to correct the label and remove non-compliant claims before selling continues.
FDA posts warning letters. Customers, competitors, retailers, and investors can all see it.
Amazon and others often delist flagged products; ignoring the letter can lead to seizure, injunction, or import refusal.
Across the label, website, and marketing — keep to structure/function language, remove anything that reads as treating or preventing a disease.
Boldface, linked to each claim, and file the 30-day notification with FDA.
Correct 101.36 panel and a clear "dietary supplement" statement of identity.
All dietary and other ingredients, the 9 allergens, and the U.S. responsible firm.
Each structure/function claim must be truthful, not misleading, and supported by evidence you can produce.
Have the label and marketing reviewed against FDA rules before printing and selling.
The claim that reads as a disease claim, the disclaimer that isn't linked right, the allergen hiding in an ingredient — these are exactly what a review catches before your product is on the market and visible to FDA. FDA Registration Assistance reviews your supplement label and marketing against the structure/function line, the DSHEA disclaimer, the allergen rules, and the Supplement Facts panel, and returns clear corrections.
Contact us at info@fdaregistrationassistance.com or call +1 (928) 275-8333. Trusted by 1,000+ clients across 135+ countries, with 15+ years of FDA experience.
Most often a disease claim — language implying the product treats, cures, or prevents a disease — which makes it an unapproved drug and misbranded. Also: incorrect Supplement Facts, missing "dietary supplement" identity, a missing or mis-linked DSHEA disclaimer, incomplete ingredients, undeclared allergens, no U.S. responsible firm, and misleading claims.
No. FDA doesn't pre-approve them, but it monitors the market and issues warning letters for non-compliant labels or marketing. The responsibility to get it right before selling is entirely the brand's.
Structure/function describes an effect on normal body structure or function ("supports memory") and is allowed with the DSHEA disclaimer. A disease claim ("treats Alzheimer's") states or implies treating/curing/preventing a disease and is not allowed — it makes the product a drug.
Yes. "Supports joint comfort" is fine; "treats arthritis" is a disease claim. The difference is the specific wording — which is why claim review is so valuable.
With any structure/function claim, the label must carry: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." Under 101.93 it's boldface and linked to each claim, and you notify FDA within 30 days of first marketing.
Per a December 2025 FDA letter, FDA intends to exercise enforcement discretion on the "each panel" requirement and may propose removing it. But it is not relaxing the core rules: the disclaimer must still be on the label and linked to each claim. Keep it and link it to each claim.
Yes — for structure/function (and general well-being and classical nutrient-deficiency) claims, submit the claim text to FDA within 30 days of first marketing. It's a notification, not approval; substantiation stays your responsibility.
Supplements use a Supplement Facts panel (101.36), not Nutrition Facts — serving size, dietary ingredients and amounts per serving, and % Daily Value where established, in the required format. Format and accuracy errors are commonly cited.
Yes. The statement of identity must include "dietary supplement" (or a descriptor like "herbal supplement"). Not identifying the product clearly is a violation.
Dietary ingredients go in the Supplement Facts panel; fillers, binders, and flavorings go in an "Other ingredients" statement. Omitting ingredients — especially an allergen source — is a frequent failure.
Yes — FALCPA applies. Declare the source of each of the 9 major allergens where present, including sesame (required since Jan 1, 2023). Undeclared allergens are high-risk.
Yes. The label must show the manufacturer, packer, or distributor's name and place of business. For imports, a U.S. responsible firm should be identified.
Yes. A safe product can still be misbranded because of its label or claims — misbranding is a leading basis for supplement enforcement and needs no safety problem.
Yes — FDA posts them publicly, so customers, competitors, retailers, and partners can find them. That visibility is a big part of the damage.
Typically within 15 working days, with corrective actions and timelines. Prompt, complete responses matter, since failing to correct can escalate enforcement.
It can escalate to product seizure, an injunction, and import refusal. Continuing to sell the non-compliant product without correcting it raises the risk.
Yes. Marketplaces often delist products under FDA enforcement or with non-compliant claims, and a public warning letter can prompt removal — compounding the impact.
Yes. FDA treats them as part of the product's labeling. A compliant bottle with disease claims online can still trigger a letter, so keep claims consistent and compliant everywhere.
Review the label and all marketing before production: substantiated structure/function claims only, DSHEA disclaimer added and notified, verified Supplement Facts and identity, complete ingredient and allergen disclosure, and the responsible firm. A pre-market review is the best safeguard.
Strongly recommended. The highest-risk issues — a claim reading as a disease claim, a mis-linked disclaimer, a hidden allergen — are easy to miss and exactly what a review catches before the product is public.
It reviews your supplement label and marketing against the structure/function line, verifies the DSHEA disclaimer and notifications, corrects the Supplement Facts panel, and confirms ingredient, allergen, and responsible-firm disclosure — returning clear corrections before you produce or sell.
Contact FDA Registration Assistance at info@fdaregistrationassistance.com or call +1 (928) 275-8333. Send your label artwork, formulation, and intended claims across label and marketing for review before market.
A general guide cannot assess the wording, context, and product information behind your particular claim. Our supplement label-review service provides documented findings, explanations, and specific corrections prioritized by risk.
See our related service and review scope.
Request Review Scope & PricingFDA Registration Assistance is a private consulting firm, not FDA. Professional assistance is not government approval or a guarantee of a regulatory outcome.
Tell us your product type, number of products, claims concern, and target date. If you have an FDA notice, identify the notice date and stated response deadline without pasting confidential correspondence. We can discuss the review scope, required materials, and pricing.
Submitting this inquiry does not purchase a service or authorize paid work. Our team can discuss the scope and required materials before you commission the review. Fields marked with an asterisk are required.